Bone marrow transplantation for low-grade B-cell malignancies

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 117-121

  Gribben, John G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; MAFOSFAMIDE; MELPHALAN;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW PURGING; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; SHORT SURVEY;

EID: 0030927544     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00002     Document Type: Short Survey

References (34)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
2. MacManus MP, Hoppe RT: Is radiotherapy curative for stage I and stage II low-grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin Oncol 1996, 14:1282-1290.
3. Coiffier B: Towards a cure in indolent lymphoproliferative diseases. Eur J Cancer 1995, 31A:2135-2137.
4. Hiddeman W: Non-Hodgkin's lymphomas: current status and future perspectives. Eur J Cancer 1996, 31A:13-14.
5. Catovsky D, Murphy RL: Key issues in the treatment of chronic lymphocytic leukemia. Eur J Cancer 1995, 31A:2146-2154.
6. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995, 333:1052-1057. A definitive review of the current status of chronic lymphocytic leukemia covering cause, diagnostic criteria, natural history, and treatment. Discusses new treatment approaches, including BMT.
7. Meehan KR, Pritchard RS, Leichter JW, Littneberg B, Welch HG: Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Am J Hematol 1995, 50:116-123.
8. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545. The definitive study to date on the role of autologous BMT in the management of relapsed NHL. Although no patients with low-grade lymphoma are included in this study, the results presented here provide the rationale for future trials of BMT in patients with NHL
9. Lazarus HM: Bone marrow transplantation in low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995, 17:199-210.
10. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Soiffer R, Coral F, Heflin L, Nadler LM: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990, 8:784-791.
11. Cervantes F, Shu XO, McGlave PB, Ramsay NK, Miller WJ, Kersey JH, Weisdorf DJ: Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995, 16:387-392. Reports the results of autologous bone marrow or PBSC transplantation in follicular lymphoma from a single center. Suggests limited results might be expected in treating patients with bulky disease or those late in their treatment course.
12. Morel P, Laporte JP, Noel MP, Lopez M, Douay L, Fouillard L, Detourmignies L, Dupriez B, Lesage S: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995, 9:576-582. Describes the use of chemotherapy purged autologous bone marrow in patients with foilicular lymphoma. Patients treated in first remission have prolonged remission compared with historical controls.
13. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996, 88:2780-2786. Large, single center pilot study of the use of autologous BMT in patients with follicular lymphoma in first remission. Patients were enrolled on an intent to treat basis, so that the potential role of BMT in this patient population can be more fully assessed.
14. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A: Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
15. Watts MJ, Jones HM, Sullivan AM, Langebeer SE, Jamieson E, Fielding A, Williams C, Berenson RJ, Goldstone AH, Linch DC: Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol 1995, 91:767-772.
16. Corringham RE, Ho AD: Rapid and sustained allogeneic transplantation using immunoselected CD34+ selected peripheral blood progenitor cells mobilized by recombinant granulocyte and granulocyte macrophage colony stimulating factors. Blood 1995, 86:2052-2054.
17. Schriber JR, Dejbakhsh-Jones S, Kusnierz-Glaz CR, Ginzton N, Still B, Negnn RS, Greenberg P, Strober S: Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. Exp Hematol 1995, 23:1024-1029.
18. Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, Blum K: Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995, 85:3334-3341.
19. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reye F, Gisslebrecht C, Coiffier B: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995, 86:3257-3262. Large study on the use of PBSC rescue after high-dose therapy. Describes more rapid engraftment and low toxicity of this approach. Results of assessment of tumor contamination in the stem cell collection will be reported separately.
20. Haas R, Moos M, Mohle R, Dohner H, Witt B, Goldshmidt H, Murea S, Flentje M, Wannermacher M, Hunstein W: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996, 17:149-155. Large study on the use of PBSC rescue after high-dose therapy. Suggests that better results may be obtained when patients are treated early in their disease course.
21. Tsatalas C, Chalkia P, Athanasiadis G, Venizelos I, Karakolios A, Papageorgiou A, Kakoulidis I, Bouicas G: Increased peripheral blood normal myeloid progenitor cells in chronic lymphocytic leukemia: a perspective for autologous peripheral blood stem cell transplantation. Eur J Haematol 1995, 54:235-240.
22. Dreger P, Kloss M, Petersen B, Haferlach T, Lofler H, Loeffler M, Schmitz N: Autologous progenitor cell transplantation: prior exposure to stem cell toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995, 86:3970-3978. Addresses the question whether stem cell toxic chemotherapy depletes hematopoietic progenitor cells. Results suggest that this may be more of a problem for PBSCs than bone marrow, and cautions that if PBSC collection is planned it should be performed before excessive exposure to these agents.
23. Moos M, Schulz R, Cremer F, Sucker C, Schmohl D, Dohner H, Goldschmidt H, Haas R, Hunstein W: Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995, 13(suppl 3):42-51.
24. Zwicky C, Maddocks A, Andersen N, Gribben JG: Eradication of polymerase chain reaction immunoglobulin gene rearrangement in non-Hodgkin's lymphoma as associated with decreased relapse after autologous bone marrow transplantation. Blood 1996, 88:3486-3491. Assesses the clinical significance of PCR detection of minimal residual disease in patients with lymphoma who do not have a t(14;18) by assessment of IgH rearrangements. Suggests that eradication of minimal residual disease is the goal of high-dose therapy.
25. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P, Weisenburger DD: Outcome of high dose therapy and autologous transplantation based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996, 14:214-219. Confirms and expands previous observations from this group suggesting that infusion of tumor cells in the autologous stem cell collection is associated with increased likelihood of relapse after autologous BMT.
26. Raspadori D, Lauria F, Ventura MA, Tazzari PL, Ferrini S, Miggiano MC, Rondell D, Tura S: Low doses of rlL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphoma. Ann Hematol 1995, 71:175-179.
27. Kramer MH, Kluin PM, Wijburg ER, Fibbe WE, Kluin-Nedemans HC: Differentiation of follicular lymphoma cells after autologous bone marrow transplantation and hematopoietic growth factor treatment. Lancet 1995, 345:488-490.
28. Milpied N, Fielding AK, Pearce RN, Ernst P, Goldstone AH: Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996, 14:1291-1296.
29. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, et al.: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994, 12:748-758.
30. Martinez C, Martino R, Brunet S, Sureda A, Nomdedeu J, Garcia A, Soler J, Domingoalbos A: Allogeneic stem cell transplantation for advanced low-grade lymphoproliferative disorders: reports of six cases. Haematologica 1996, 81:33-34.
31. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC. Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, et al.: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996, 100:299-307. Large series describing the role of allogeneic BMT in patients with lymphoma. Included are a number of patients with follicular lymphoma who appear to have excellent disease-free survival after allogeneic BMT.
32. Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, et al.: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366-1376.
33. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton E, Rozman C, Gratwohl A, Gale RP: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia: European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern med 1996, 124:311-315. Largest reported series of BMT in chronic lymphocytic leukemia. Includes registry data from the European Bone Marrow Transplant Registry and the International Bone Marrow Transplant Registry. Unacceptably high treatment-related morbidity and mortality are reported in this series.
34. Provan D, Zwicky C, Bartlett-Pandite L, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG: Eradication of PCR detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235. Assesses the potential of high-dose therapy and allogeneic or autologous BMT to eradicate PCR-detectable minimal residual disease. Those patients with persistence of disease after high-dose therapy invariably relapsed. Suggests that PCR-detectable disease may have to be eradicated for cure.